CoChat
Sign Up
Cited by 158Nonmelanoma Skin Cancer StudiesPhotodynamic Therapy Research StudiesHead and Neck Cancer Studies

Photodynamic therapy with topical methyl aminolaevulinate for 'difficult-to-treat' basal cell carcinoma

Vinciullo, C., Elliott, T., Francis, D., Gebauer, K., Spelman, L., Nguyen, R., Weightman, W., Sheridan, A. +3 more·2005·British Journal of Dermatology
DOI 10.1111/j.1365-2133.2005.06484.x
Open this paper in CoChat — free account

Abstract

BACKGROUND: Basal cell carcinoma (BCC) may be difficult to treat by conventional means, particularly if the lesions are large or located in the mid-face (H-zone). Photodynamic therapy (PDT) using topical methyl aminolaevulinate (MAL) may be a good noninvasive option for these patients. OBJECTIVES: To investigate the efficacy and safety of PDT using MAL for BCCs defined as 'difficult to treat', i.e. large lesions, in the H-zone, or in patients at high risk of surgical complications. METHODS: This was a prospective, multicentre, noncomparative study. Patients were assessed 3, 12 and 24 months after the last PDT treatment. One hundred and two patients with 'difficult-to-treat' BCC were treated with MAL PDT, using 160 mg g(-1) cream and 75 J cm(-2) red light (570-670 nm), after lesion preparation and 3 h of cream exposure. Results Ninety-five patients with 148 lesions were included in the per protocol analysis. The histologically confirmed lesion complete response rate at 3 months was 89% (131 of 148). At 12 months, 10 lesions had reappeared, and therefore the cumulative treatment failure rate was 18% (27 of 148). At 24 months, an additional nine lesions had reappeared, resulting in a cumulative treatment failure rate of 24% (36 of 148). The estimated sustained lesion complete response rate (assessed using a time-to-event approach) was 90% at 3 months, 84% at 12 months and 78% at 24 months. Overall cosmetic outcome was judged as excellent or good in 79% and 84% of the patients at 12 and 24 months, respectively. Follow-up is continuing for up to 5 years. CONCLUSIONS: MAL PDT is an attractive option for 'difficult-to-treat' BCC. Because of the excellent cosmetic results, the treatment is particularly well suited for lesions that would otherwise require extensive surgical procedures.

Integrity signals

Registry

Crossref · 10.1111/j.1365-2133.2005.06484.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In treatment of large lesions or more aggressive lesions with H-zone in patients with high risk of surgery, Viniciullo et al. received 90% of complete response after 3 months, which had decreased to 78% following the next 18 months.

    “However, in the treatment of large lesions or more aggressive lesions with H-zone in patients with high risk of surgery, Viniciullo et al. received a 90% of complete response after 3 months, which had decreased to 78% following next 18 months [134].”

    From Aminolevulinic Acid (ALA) as a Prodrug in Photodynamic Therapy of Cancer (2011) · cites this paper as [134]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Vinciullo, C., Elliott, T., Francis, D., Gebauer, K., Spelman, L., Nguyen, R., Weightman, W., Sheridan, A., Reid, C., Czarnecki, D., & Murrell, D.
Affiliations
  • Fremantle Hospital (AU)
  • Royal Adelaide Hospital (AU)
Corresponding author
Vinciullo, C.
ORCID
Venue
British Journal of Dermatology
Publisher
Oxford University Press (OUP)
Published
2005-04
Volume
152
Issue
4
Pages
765-772
ISSN
  • 0007-0963 (ISSN-L)
  • 1365-2133
DOI
10.1111/j.1365-2133.2005.06484.x
OpenAlex
W2139525078
Cited by
158
References
1
Citations by year
2026: 2 · 2025: 2 · 2024: 1 · 2023: 6 · 2022: 6 · 2021: 4 · 2020: 7 · 2019: 4 · 2018: 5 · 2017: 7 · 2016: 11 · 2015: 8 · 2014: 6 · 2013: 8 · 2012: 6
FWCI
9.61
Type
journal article
Language
en
Open access
closed
Licence
doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 3805 d)
Locations
  • British Journal of Dermatology (publishedVersion)
  • PubMed (publishedVersion)
  • Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
Funders
University of South Australia
Topics
  • Health Sciences › Medicine › Epidemiology › Nonmelanoma Skin Cancer Studies
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Photodynamic Therapy Research Studies
  • Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
Keywords
basal cell carcinoma, photodynamic therapy, methyl aminolaevulinate, facial skin cancer, treatment failure, cosmetic outcome, non-invasive treatment, red light
MeSH terms
Administration, Topical, Adult, Aged, Aged, 80 and over, Aminolevulinic Acid, Carcinoma, Basal Cell, Basal Cell Carcinoma, Female, Humans, Male, Middle Aged, Photochemotherapy, Prospective Studies, Risk Factors, Skin Neoplasms, Time Factors, Treatment Outcome, Patient Satisfaction, Treatment Failure, Photosensitizing Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review